JNJ
Johnson & Johnson (JNJ) TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Sec Form 10K
Johnson & Johnson (NYSE: JNJ) Sec Form 10K
Johnson & Johnson (JNJ) Barclays 28th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) FY 2026 Corporate Conference
Johnson & Johnson (JNJ) Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2025 Earnings Call dated Jan. 21, 2026 Corporate Participants: Darren Snellgrove — Vice President…